Toxicity and Solution of Trastuzumab Combined Therapy
DOI:
https://doi.org/10.54097/16mvdd71Keywords:
Trastuzumab, cancer therapy, combination therapy, HER-2Abstract
Trastuzumab is a kind of monoclonal antibody widely used in cancer, especially in breast and stomach cancer. Due to the HER-2 expression in cardiomyocytes, it is most likely to affect normal cardiac function. Although combination therapies can reduce its toxicity to some extent, we still found toxicity in some combination therapies. In this review, we aim to summarize and analyze the toxicity found in combination therapy and give novel solutions to them. We have analyzed the combination toxicity including trastuzumab with ACE inhibitor, premedication, Emtansine, doxorubicin, and anthracycline taxane chemotherapy regimen. And we chose two main solutions as examples, including serum biomarkers and zingerone.
Downloads
References
Le X-F, Pruefer F, Bast R C. HER2-targeting Antibodies Modulate the Cyclin-dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways. Cell Cycle, Taylor & Francis, 2005, 4(1): 87–95.
Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature, 1984, 312(5994): 545-548.
Nahta R, Esteva F J. HER-2-targeted therapy: lessons learned and future directions. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2003, 9(14): 5078–5084.
A D, Z R, H S, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. Journal of Cellular Physiology, J Cell Physiol, 2020, 235(4): 3142-3156.
Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat, 2019, 177(2): 237-250.
Nicolazzi MA, Carnicelli A, Fuorlo M, et al. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci, 2018, 22(7): 2175-2185.
Nakagami H, Takemoto M, Liao J K. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. Journal of Molecular and Cellular Cardiology, 2003, 35(7): 851–859.
Pichler W J. Adverse side‐effects to biological agents. Allergy, 2006, 61(8): 912-920.
Mo H, Jazieh K A, Brinzevich D, et al. A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. Clinical Breast Cancer, 2022, 22(1): 1–9.
Vahid B, Mehrotra A. Trastuzumab (Herceptin)-associated lung injury. Respirology, 2006, 11(5): 655-658.
Cardinale D, Colombo A, Sandri M T, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, 2006, 114(23): 2474–2481.
Brennan P J, Rodriguez Bouza T, Hsu F I, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. The Journal of Allergy and Clinical Immunology, 2009, 124(6): 1259–1266.
Goto E, Hata T, Nishihara M, et al. Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab. British Journal of Clinical Pharmacology, 2023, 89(7): 2102–2112.
Rombouts M D, Swart E L, VAN DEN Eertwegh A J M, et al. Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. Anticancer Research, 2020, 40(3): 1201–1218.
Egloff H, Kidwell K M, Schott A. Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review. Case Reports in Oncology, 2018, 11(2): 527–533.
Milano G, Biemmi V, Lazzarini E, et al. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity. Cardiovascular Research, 2020, 116(2): 383–392.
Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta, 2016, 1863: 1916-1925.
Genuino AJ, Chaikledkaew U, The DO, et al. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Rev Clin Pharmacol, 2019, 12(8): 815-824.
Pudil R, Mueller C, Čelutkienė J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22(11): 1966–1983.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
